A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV

The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.

Study Overview

• Status: Completed
• Conditions: Respiratory Syncytial Virus Infection Prevention
• Intervention / Treatment: Biological: Ad26.RSV.preF-based Vaccine; Other: Placebo

Detailed Description

RSV is an important cause of serious respiratory infections in adults aged 60 years and older, immunocompromised individuals, and those with underlying chronic cardiopulmonary conditions. The current study assess the safety and immunogenicity of the RSV vaccine in adults 18 to 59 years of age, including those who are at risk for severe RSV disease. The study comprises screening (pre-vaccination) and vaccination for each participant on Day 1, and a 6- month safety and immunogenicity follow-up period. The study duration will be up to 6 months per participant. Assessments like immunogenicity (such as humoral and cellular immune responses), safety (such as monitoring of AEs, physical examinations, and vital signs) and reactogenicity will be performed in this study.

• Study Type: Interventional
• Enrollment (Actual): 1124
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Alken, Belgium, 3570
    • Anima
  • Bruxelles, Belgium
    • C.H.U. St Pierre / Maladies Infectieuses
  • Namur, Belgium, 5101
    • Private Practice RESPISOM Namur
• Germany
  • Berlin, Germany, 10629
    • emovis GmbH
  • Berlin, Germany, 10787
    • Klinische Forschung Berlin GbR
  • Dresden, Germany, 01069
    • Klinische Forschung Dresden GmbH
  • Hamburg, Germany, 22143
    • Clinical Research HamburggmbH
  • Koeln, Germany, 51069
    • Zentrum fuer klinische Forschung
  • Leipzig, Germany, 04103
    • SIBAmed GmbH & Co. KG
  • Schwerin, Germany, 19055
    • Klinische forschung Schwerin GmbH
• Spain
  • Córdoba, Spain, 14004
    • Hosp Reina Sofia
  • Málaga, Spain, 29010
    • Hosp Virgen de La Victoria
• Sweden
  • Lund, Sweden, 22222
    • ProbarE i Lund AB
  • Solna, Sweden, 171 64
    • ClinSmart Sweden AB
  • Stockholm, Sweden, 113 29
    • ProbarE i Stockholm AB
  • Stockholm, Sweden, 11361
    • Studieenheten Akademiskt Specialistcentrum Stockholm
• United States
  • Florida
    • Coral Gables, Florida, United States, 33134
      • Alliance for Multispeciality Research
    • Miami, Florida, United States, 33173
      • Research Institute of South Florida Inc
  • Kansas
    • El Dorado, Kansas, United States, 67042
      • Heartland Research Associates, an AMR Company
  • Louisiana
    • New Orleans, Louisiana, United States, 70119
      • AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company
  • Maryland
    • Rockville, Maryland, United States, 20854
      • Meridian Clinical Research, LLC
  • Oklahoma
    • Yukon, Oklahoma, United States, 73099
      • Tekton Research Inc.
  • Tennessee
    • Knoxville, Tennessee, United States, 37909
      • Alliance for Multispeciality Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Participants must be of a) non child bearing potential or b) of child bearing potential and practicing an acceptable and effective of contraception
• All participants of childbearing potential must: have a negative highly sensitive urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening; and have a negative highly sensitive urine beta-hCG pregnancy test immediately prior to each study vaccination (if screening and vaccination are not performed on the same day) Cohorts 1 and 2
• Participant is aged 18 to 59 years (inclusive) on the day of signing the informed consent form (ICF) and expected to be available for the duration of the study Cohort 2
• Has an existing chronic heart or lung condition, without hospitalizations or major medication class change (that is, new or stopped medications) within 30 days prior to screening, meeting the following criteria; a) cardiac disease: at least Class II symptoms per New York Heart Association classification or similar guidelines according to local practice, b) pulmonary disease: activity-restricting symptoms or use of long-term medications Cohort 3
• Participant is aged 65 years or older on the day of signing the ICF and expected to be available for the duration of the study
• Participant may have underlying illnesses such as hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable at the time of vaccination, and these conditions receive routine follow-up by the participant's healthcare provider

Exclusion Criteria:

• Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
• Abnormal function of immune system due to a clinical condition or treatment
• History of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced thrombocytopenia and thrombosis (HITT).
• Participant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of study vaccine; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of study vaccine
• Received an respiratory syncytial virus (RSV) vaccine in a previous RSV vaccine study
• History of acute polyneuropathy (example, Guillain-Barre syndrome) or chronic idiopathic demyelinating polyneuropathy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine); Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.	Biological: Ad26.RSV.preF-based Vaccine; Participants will receive a single IM injection of an RSV vaccine.
Placebo Comparator: C1 G2: Healthy Adults, 18-59 Years (Placebo); Participants will receive a single IM injection of matching placebo on Day 1.	Other: Placebo; Participants will receive a single IM injection of matching placebo.
Experimental: C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine); Participants will receive a single IM injection of study vaccine on Day 1.	Biological: Ad26.RSV.preF-based Vaccine; Participants will receive a single IM injection of an RSV vaccine.
Placebo Comparator: C2 G4: High Risk Adult, 18-59 Years (Placebo); Participants will receive a single IM injection of matching placebo on Day 1.	Other: Placebo; Participants will receive a single IM injection of matching placebo.
Experimental: C3 G5: Adults, 65 Years and Older (RSV Vaccine); Participants will receive a single IM injection of study vaccine on Day 1.	Biological: Ad26.RSV.preF-based Vaccine; Participants will receive a single IM injection of an RSV vaccine.
Placebo Comparator: C3 G6: Adults, 65 Years and Older (Placebo); Participants will receive a single IM injection of matching placebo on Day 1.	Other: Placebo; Participants will receive a single IM injection of matching placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cohorts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs)	Number of participants with solicited local AEs at 7 days post-vaccination in Cohorts 1 and 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs were predefined local events (at the injection site: erythema, pain/tenderness and swelling) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.	7 days after vaccination on Day 1 (Day 8)
Cohorts 1 and 2: Number of Participants With Solicited Systemic AEs	Number of participants with solicited systemic AEs at 7 days post-vaccination in Cohorts 1 and 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic AEs including pyrexia, headache, fatigue, myalgia and nausea were collected within 7 days after vaccination.	7 days after vaccination on Day 1 (Day 8)
Cohorts 1 and 2: Number of Participants With Unsolicited AEs	Number of participants with unsolicited AEs post-vaccination in Cohorts 1 and 2 were reported. An AE was defined as any untoward medical occurrence in a participant participating in a clinical study that did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were defined as all AEs for which the participant was not specifically questioned in the participant diary.	28 days after vaccination on Day 1 (Day 29)
Cohorts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs)	Number of participants with SAEs post-vaccination were reported. An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above.	6 months after vaccination on Day 1 (Day 183)
Cohorts 1, 2, and 3: Number of Participants With Adverse Events of Special Interest (AESI)	Number of participants with AESI post-vaccination were reported. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Thrombosis with thrombocytopenia syndrome (TTS) was considered as an AESI.	6 months after vaccination on Day 1 (Day 183)
Cohorts 1 (Group 1), 2 (Group 3), and 3 (Group 5): Respiratory Syncytial Virus (RSV) A2 Strain Neutralizing Antibody Titers	RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay and were expressed as 50% inhibitory concentration (IC50) units.	14 days after vaccination on Day 1 (Day 15)
Cohorts 1 (Group 1), 2 (Group 3), and 3 (Group 5): Percentage of Participants With Seroresponse as Assessed by Virus Neutralizing Assay (VNA-A2)	Percentage of participants with seroresponse as assessed by VNA-A2 strain were reported. Seroresponse was defined as a 4-fold increase from baseline in Day 15 VNA A2 antibody titers.	14 days after vaccination on Day 1 (Day 15)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cohorts 1, 2, and 3: Geomteric Mean Titers (GMTs) of RSV Fusion Protein (F-protein) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)- Pre-Fusion	GMTs of RSV Fusion Protein (PreF) antibodies as assessed by ELISA-Pre-Fusion at Day 15 were reported.	14 days after vaccination on Day 1 (Day 15)

Collaborators and Investigators

• Sponsor: Janssen Vaccines & Prevention B.V.
• Investigators: Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.

Study record dates

Study Major Dates

• Study Start (Actual): September 29, 2021
• Primary Completion (Actual): August 12, 2022
• Study Completion (Actual): August 12, 2022

Study Registration Dates

• First Submitted: September 27, 2021
• First Submitted That Met QC Criteria: September 27, 2021
• First Posted (Actual): October 7, 2021

Study Record Updates

• Last Update Posted (Actual): May 25, 2025
• Last Update Submitted That Met QC Criteria: May 22, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Pneumovirus Infections; Paramyxoviridae Infections; Mononegavirales Infections; Infections; Respiratory Syncytial Virus Infections
• Other Study ID Numbers: CR109038; 2021-001909-77 (EudraCT Number); VAC18193RSV3006 (Other Identifier: Janssen Vaccines & Prevention B.V.)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No